AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Macrophage-stimulating protein receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q04912

UPID:

RON_HUMAN

Alternative names:

CDw136; Protein-tyrosine kinase 8; p185-Ron

Alternative UPACC:

Q04912; A0A087WZG2; B5A944; B5A945; B5A946; B5A947

Background:

The Macrophage-stimulating protein receptor, known alternatively as CDw136, Protein-tyrosine kinase 8, and p185-Ron, plays a pivotal role in cellular processes. It transduces signals from the extracellular matrix to the cytoplasm by binding to MST1 ligand, influencing cell survival, migration, and differentiation. Activation of RON triggers several signaling cascades, including RAS-ERK, PI3 kinase-AKT, and PLCgamma-PKC, crucial for wound healing and the innate immune response.

Therapeutic significance:

Given its involvement in nasopharyngeal carcinoma, understanding the role of the Macrophage-stimulating protein receptor could open doors to potential therapeutic strategies. Its ability to regulate cell migration, proliferation, and survival highlights its potential as a target for innovative cancer treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.